Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Epinephrine acts as a vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing local blood flow and prolonging anesthetic effect.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Local anesthesia for infiltration, nerve block, and epidural anesthesia,Dental anesthesia,Surgical procedures requiring local anesthesia
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
1-2 m L of 2% lidocaine (20-40 mg) with epinephrine 1:100,000 (0.01-0.02 mg epinephrine) injected locally; maximum single dose 7 mg/kg lidocaine (7 m L/kg of 0.1% solution equivalent).
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Alphacaine: 1.5-2 hours; epinephrine: 2-3 minutes. Clinical context: The duration of local anesthesia is prolonged by epinephrine-induced vasoconstriction, not by the half-life of alphacaine.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Lidocaine is primarily metabolized in the liver via CYP3A4 and CYP1A2 to monoethylglycinexylidide (MEGX) and glycinexylidide (GX). Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily renal excretion of metabolites and unchanged drug; <5% excreted unchanged in urine. Biliary excretion accounts for a minor fraction.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Alphacaine: 55-65% bound to alpha-1-acid glycoprotein; Epinephrine: minimal binding (15-20% to albumin).
~10-20% bound to plasma proteins (primarily albumin).
Alphacaine: 1.0-1.5 L/kg, indicating extensive tissue distribution; Epinephrine: 0.2-0.4 L/kg, reflecting rapid uptake into adrenergic tissues.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Intravenous: 100%; Oral: negligible (high first-pass metabolism); Topical: variable (minimal systemic absorption); Local injection: essentially 100% at the site but systemic bioavailability is reduced by epinephrine.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No specific dose adjustment required; lidocaine clearance minimally affected by renal impairment. Epinephrine use with caution if severe renal impairment due to potential vasoconstrictor effects.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh Class A: 60-80% of normal dose; Class B: 40-60% of normal dose; Class C: 20-40% of normal dose; reduce maximum single dose to 70% of standard in severe impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Weight-based: 1-2 mg/kg lidocaine with epinephrine 1:100,000 (0.009-0.018 mg/kg epinephrine) for local infiltration; maximum single dose 4.5 mg/kg lidocaine (0.045 m L/kg of 1% solution).
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Start with lowest effective dose (e.g., 0.5-1 m L of 2% lidocaine with epinephrine); reduce maximum single dose to 80% of adult maximum; monitor for cardiovascular effects of epinephrine.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Not for use in obstetrical paracervical block anesthesia due to risk of fetal bradycardia and fetal death.
None
Risk of systemic toxicity including CNS and cardiac effects,Use with caution in patients with hepatic impairment or severe renal disease,Avoid inadvertent intravascular injection,Epinephrine may cause tachycardia, hypertension, and arrhythmias,Use minimum effective dose,Monitor for signs of methemoglobinemia
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to amide-type anesthetics,Severe hypotension,Concurrent use of MAO inhibitors or tricyclic antidepressants (relative),Shock,Avoid use in areas with poor blood supply
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
No significant food interactions. Avoid hot liquids or food until numbness resolves to prevent oral burns.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Pregnancy category C. First trimester: Lidocaine crosses placenta; epinephrine may reduce uterine blood flow. No well-controlled human studies; animal studies show fetal harm at high doses. Second trimester: Similar risks; avoid near cervix to prevent systemic absorption. Third trimester: Placental transfer increases; risk of fetal acidosis, bradycardia, and neurobehavioral depression with high doses.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Lidocaine and epinephrine are excreted in breast milk in low amounts. Lidocaine M/P ratio ~0.5; epinephrine M/P ratio unknown. Infant dose via milk is ~1-2% of maternal weight-adjusted dose. Risk of neonatal bradycardia or irritability is low with standard doses. Use caution with high doses or repeated administration.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Pregnancy increases plasma volume and metabolism; no specific dose adjustments recommended for lidocaine or epinephrine. Use lowest effective dose and concentration to minimize fetal exposure. Avoid intra-arterial injection and use with caution in preeclampsia or compromised placental perfusion.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Alphacaine Hydrochloride w/ Epinephrine is a dental local anesthetic solution containing lidocaine HCl 2% with epinephrine 1:100,000 or 1:50,000. The epinephrine component provides vasoconstriction, prolonging anesthetic duration and reducing systemic absorption. Maximum dose of lidocaine with epinephrine is 7 mg/kg (not to exceed 500 mg). For dental infiltration, use smallest effective volume. Avoid intravascular injection; aspirate before injection. Use caution in patients with severe cardiovascular disease, hypertension, hyperthyroidism, or those on MAOIs or tricyclic antidepressants due to potential for hypertensive crisis. Epinephrine may cause tachycardia or hypertension. Do not use in patients with allergy to amide anesthetics or sulfites (present in some formulations).
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
This medication is a local anesthetic used to numb a specific area in your mouth for dental procedures.,You may feel a burning sensation during injection, but numbness should set in quickly.,Avoid eating or drinking hot beverages for at least 1 hour after the procedure to prevent burns while numb.,Do not chew on the numb side until sensation returns fully.,If you experience chest pain, palpitations, severe headache, or difficulty breathing, seek emergency medical attention immediately.,Report any signs of allergic reaction such as rash, swelling, or difficulty breathing to your dentist or doctor.,Inform your dentist of all medications you take, especially MAOIs, tricyclic antidepressants, beta-blockers, or thyroid medications.,This medication contains epinephrine, which can raise heart rate and blood pressure.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
"Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension."
"Epinephrine, a non-selective alpha and beta adrenergic agonist, can antagonize the antihypertensive effects of clomipramine, a tricyclic antidepressant (TCA) that inhibits norepinephrine reuptake. Concomitant use may lead to enhanced sympathetic activity, potentially causing severe hypertension, tachycardia, and increased risk of arrhythmias. This interaction is particularly concerning during local anesthetic procedures involving epinephrine or systemic administration in patients on clomipramine."
"Epinephrine, a sympathomimetic amine with potent beta-2 adrenergic agonist activity, can directly antagonize the insulin-sensitizing effects of pioglitazone by stimulating glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output and reduced peripheral glucose uptake. This functional antagonism may result in a significant elevation of blood glucose levels, thereby diminishing the therapeutic efficacy of pioglitazone in managing type 2 diabetes. In diabetic patients, the interaction may precipitate acute hyperglycemia, requiring dosage adjustments or alternative therapeutic strategies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE vs ALDOMET, answered by our medical review team.
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is a Alpha/Beta Agonist that works by Lidocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Epinephrine acts as a vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing local blood flow and prolonging anesthetic effect.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is: 1-2 m L of 2% lidocaine (20-40 mg) with epinephrine 1:100,000 (0.01-0.02 mg epinephrine) injected locally; maximum single dose 7 mg/kg lidocaine (7 m L/kg of 0.1% solution equivalent).. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE is classified as Category A/B. Pregnancy category C. First trimester: Lidocaine crosses placenta; epinephrine may reduce uterine blood flow. No well-controlled human studies; animal studies show fetal harm at hi. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.